Abbott Acquires Veropharm To Expand Presence In Russia

The deal makes sense in light of Abbott's recent efforts to expand its generic drug business in high-growth emerging markets such as China, India, Latin America and Russia because of sustained sluggishness in developed markets. This deal follows Abbott's recent $2.9 billion acquisition of Chile-based CFR Pharmaceuticals to expand its presence in Latin America.